<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Among 354 adult patients with either <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e> or <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, eight were positive for anti-HTLV-I antibodies; six of eight had received multiple transfusions </plain></SENT>
<SENT sid="1" pm="."><plain>There was an approximately 3.5-fold increase (P less than .001) of HTLV-I seropositivity in the patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic disease</z:e> (8 of 354, 2.23%) compared to the healthy adults older than 20 years (34 of 5252, .65%) </plain></SENT>
<SENT sid="2" pm="."><plain>Two hematological patients, one with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> and one with <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo>, were found to be positive for HTLV-I, and developed and died of adult T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (ATL) subsequently </plain></SENT>
<SENT sid="3" pm="."><plain>Both were long-term survivors of the <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary disease</z:e> and had received multiple transfusions </plain></SENT>
<SENT sid="4" pm="."><plain>The latent period from blood transfusion to <z:hpo ids='HP_0003674'>onset</z:hpo> of ATL was 6 months and 11 years, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Immunocompromised patients, who were seropositive for HTLV-I, may be at increased risk for ATL compared to healthy carriers of HTLV-I, and the latent period may be shorter </plain></SENT>
</text></document>